CN103249732B - 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii - Google Patents

抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii Download PDF

Info

Publication number
CN103249732B
CN103249732B CN201180059188.1A CN201180059188A CN103249732B CN 103249732 B CN103249732 B CN 103249732B CN 201180059188 A CN201180059188 A CN 201180059188A CN 103249732 B CN103249732 B CN 103249732B
Authority
CN
China
Prior art keywords
alkyl
methyl
piperidine
mmol
benzothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180059188.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103249732A (zh
Inventor
J·T·帕尔默
C·J·鲁尼斯
D·A·奥夫曼
L·C·阿克斯福德
M·布莱尔
D·R·米歇尔
N·J·帕尔默
C·斯蒂尔
J·阿瑟奥
D·沃森
D·J·海顿
L·G·洽普勒斯基
D·戴维斯
I·克林斯
E·M·泰恩戴尔
L·安德罗
G·R·W·皮特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Europe Ltd
Original Assignee
Biota Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Europe Ltd filed Critical Biota Europe Ltd
Publication of CN103249732A publication Critical patent/CN103249732A/zh
Application granted granted Critical
Publication of CN103249732B publication Critical patent/CN103249732B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/28Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
    • A01N47/36Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N< containing the group >N—CO—N< directly attached to at least one heterocyclic ring; Thio analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201180059188.1A 2010-10-08 2011-10-07 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii Expired - Fee Related CN103249732B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39116310P 2010-10-08 2010-10-08
US61/391,163 2010-10-08
PCT/AU2011/001284 WO2012045124A1 (en) 2010-10-08 2011-10-07 Bacteria topoisomerase ii inhibiting 2-ethylcarbamoylamino-1, 3-benzothiazol-5-yls

Publications (2)

Publication Number Publication Date
CN103249732A CN103249732A (zh) 2013-08-14
CN103249732B true CN103249732B (zh) 2016-08-10

Family

ID=45925612

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180059188.1A Expired - Fee Related CN103249732B (zh) 2010-10-08 2011-10-07 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii

Country Status (6)

Country Link
US (1) US9181234B2 (enExample)
EP (1) EP2625178A4 (enExample)
JP (1) JP5864589B2 (enExample)
CN (1) CN103249732B (enExample)
AU (1) AU2011313820A1 (enExample)
WO (1) WO2012045124A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824519C (en) 2011-01-14 2020-06-16 Vertex Pharmaceuticals Incorporated Process of making gyrase and topoisomerase inhibitors
TW201309676A (zh) 2011-01-14 2013-03-01 Vertex Pharma 旋轉酶抑制劑(r)-1-乙基-3-[5-[2-(1-羥基-1-甲基-乙基)嘧啶-5-基]-7-(四氫呋喃-2-基]-1h-苯并咪唑-2-基]脲之固體形式
EP2663562B1 (en) 2011-01-14 2018-11-07 Spero Trinem, Inc. Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
JP6085829B2 (ja) 2011-01-14 2017-03-01 スペロ トリネム, インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼiv阻害剤
TWI554515B (zh) 2011-06-20 2016-10-21 維泰克斯製藥公司 旋轉酶(gyrase)及拓樸異構酶抑制劑之磷酸酯
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
WO2014015105A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
JP2017504662A (ja) 2014-02-03 2017-02-09 スペロ ジャイレース インク ポリミキシンを含む抗菌剤の組合せ
CN104230991A (zh) * 2014-08-25 2014-12-24 亿腾药业(泰州)有限公司 一种控制福沙吡坦二甲葡胺中钯残留的方法
KR101987994B1 (ko) 2015-01-28 2019-06-11 제이엔 테라퓨틱스 치환된 이미다조[1,2-a]피리딘-2-일아민 화합물, 및 약학 조성물 및 이의 사용 방법
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
EP3436461B1 (en) 2016-03-28 2023-11-01 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CN110267960B (zh) * 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
KR20190133667A (ko) 2017-03-24 2019-12-03 다이쇼 세이야꾸 가부시끼가이샤 2(1h)-퀴놀리논 유도체
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル,インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
MX2022001861A (es) * 2019-08-15 2022-03-11 Bayer Ag Procedimiento para la preparacion de 2-(fenilimino)-3-alquil-1,3-t iazolidin-4-onas.
CN115315425B (zh) * 2020-08-14 2025-03-28 上海复旦张江生物医药股份有限公司 一种取代的咪唑并[1,2-a]吡啶-2-基酰胺化合物的制备方法及其中间体
CN115073358B (zh) * 2022-07-21 2023-09-26 安徽德诺医药股份有限公司 一种n-苄基-4-哌啶甲酸乙酯的制备方法
CN118955404A (zh) * 2024-07-30 2024-11-15 凯美克(上海)医药科技有限公司 一种化合物3,5-二溴哒嗪的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
ES2331250T3 (es) * 2000-12-15 2009-12-28 Vertex Pharmaceuticals Incorporated Inhibidores de la girasa bacteriana y usos de los mismos.
US7618974B2 (en) * 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8404852B2 (en) * 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CA2648748A1 (en) * 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
GB0724342D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
EP2321309A1 (en) * 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
WO2010100144A1 (en) * 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase

Also Published As

Publication number Publication date
JP5864589B2 (ja) 2016-02-17
EP2625178A4 (en) 2014-04-30
US9181234B2 (en) 2015-11-10
US20120088750A1 (en) 2012-04-12
JP2013542204A (ja) 2013-11-21
CN103249732A (zh) 2013-08-14
WO2012045124A1 (en) 2012-04-12
AU2011313820A1 (en) 2013-04-11
EP2625178A1 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
CN103249732B (zh) 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii
AU2016347456B2 (en) Peptide macrocycles against acinetobacter baumannii
DE602004009089T2 (de) Pyrrolderivate mit antibakterieller wirkung
CN109890822B (zh) 细胞代谢过程的抑制剂
JP6549703B2 (ja) 新規化合物
JP7033079B2 (ja) 芳香族スルホンアミド誘導体
CN102746239B (zh) 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102015686B (zh) 杂环化合物及其用途
CN101163693B (zh) 抗菌哌啶衍生物
CN101868459B (zh) 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物
CN102015699A (zh) 杂环脲衍生物及其使用方法-211
TWI628174B (zh) 新穎吡啶衍生物
CN101472585A (zh) 抗菌组合物
TWI715569B (zh) 6員雜環衍生物及含有彼等之醫藥組合物
WO2020147739A1 (zh) 溶血磷脂酸受体拮抗剂及其制备方法
TW200831503A (en) Chemical compounds
SA517381129B1 (ar) -2(1h)- مشتقات بيريدين ون كوينولينون كمثبطات أيزو سيترات ديهيدروجيناز- طافرة
CN104125947A (zh) 杂环脲化合物
CN111925367A (zh) 稠环类衍生物抑制剂、其制备方法和应用
TW201111380A (en) Heterocyclic urea derivatives and methods of use thereof
UA82261C2 (uk) Похідні піролу з антибактеріальною дією
KR20240128969A (ko) 헤테로방향족 질소산화물 화합물, 이의 제조방법 및 이의 용도
CN116529246A (zh) 用于治疗和预防乙型肝炎病毒感染的n-[(1,3-苯并噁唑-2-基)-杂环]酰胺衍生物
CA2992926C (en) Peptide macrocycles against acinetobacter baumannii
WO2023125812A1 (zh) 取代的嘧啶酮衍生物、其药物组合物及医药上的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160810

Termination date: 20171007

CF01 Termination of patent right due to non-payment of annual fee